Companies developing PCR or related nucleic acid amplification and detection technologies primarily for diagnostic purposes have garnered more than $9 million in grants from the Internal Revenue Service under a program designed to support new cost-saving therapies, create jobs, and increase US competitiveness.
The grants, awarded through the Qualifying Therapeutic Discovery Project Program created by the Patient Protection and Affordable Care Act of 2010, were disclosed last week by the IRS.
Under the program, a total of $1 billion was allocated for tax credits and grants for the 2009 and 2010 tax years with a $5 million limit per each eligible applicant.
While a majority of the awards support therapeutic development at US companies, several million dollars worth of grants will fund the commercialization of molecular biology tools, such as PCR, proteomics, sequencing, bioinformatics, and arrays, for diagnostic development or drug discovery applications.
Following is a state-by-state listing of companies awarded grants to develop and/or commercialize PCR, nucleic acid-detection, or sample preparation technologies. Note that this is not a comprehensive list of awards made under the program; and, in many cases, awardees may have received additional grants for other types of technologies. A full list of awards can be found here.
